None of the new HBV agents is in phase-3 yet. Moreover, all of the clinical programs for these agents are aiming for 2- or 3-drug combination regimens after initial testing on monotherapies.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”